Diabetes Dialogue: April 2022 Edition

Podcast

In the April 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini discuss the implications of the FDA's approval of semaglutide 2.0 mg, the use of novel glycemic control metrics, and a preview of ATTD 2022.

Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives is available in an audio-only format on Spotify and Apple Podcasts.

Related Videos
Ghada Bourjeily, MD: Research Gaps on Sleep Issues During Pregnancy
John Winkelman, MD, PhD: When to Use Low-Dose Opioids for Restless Legs Syndrome
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Jennifer Martin, PhD: Boosting CPAP Adherence in Women with Sleep Apnea
Video 2 - 4 KOLs are featured in, "Educating Primary Care Clinicians on Outpatient HE Management and Ammonia Testing"
Video 1 - 4 KOLs are featured in, "Exploring the Impact of Hepatic Encephalopathy on Patients and Their Families "
Related Content
James Galloway, MBChB | Credit: Galapagos Health

Certolizumab Pegol Offers Consistent Benefit, Regardless of Rheumatoid Factor Levels

Patrick Campbell
June 14th 2024
Article
New Insight with Veeral Sheth, MD Podcast logo | Image Credit: HCPLive

New Insight: A Look at the OcuLenz with Michael Freeman, CEO of Ocutrx

Connor Iapoce
June 11th 2024
Podcast
Upadacitinib Led to Sustained, 140-Week Improvements for Atopic Dermatitis Patients

Upadacitinib Led to Sustained, 140-Week Improvements for Atopic Dermatitis Patients

Tim Smith
June 13th 2024
Article
Diabetes Dialogue: GLAM and CRISTAL, Updates in Pregnancy

Diabetes Dialogue: GLAM and CRISTAL, Updates in Pregnancy

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
June 5th 2024
Podcast
Pilar Serra-Añó, PhD | Credit: University of Valencia

Low-Pressure Hyperbaric Oxygen Therapy May Aid Pain Management in Women with Fibromyalgia

Abigail Brooks, MA
June 13th 2024
Article
Bimekizumab Response is Sustained Over 4 Years in Plaque Psoriasis

Bimekizumab Response is Sustained Over 4 Years in Plaque Psoriasis

Lana Pine
June 13th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.